A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

NCT06092931 | Completed Phase 1 FDA Drug

• 1 other identifier: DCE806104
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

The main objective of this study is to assess the effect of DC-806 on the pharmacokinetics (PK) of cytochrome 3A4 (CYP3A4) substrate, midazolam and its active metabolite, 1-hydroxymidazolam, cytochrome 2C8 (CYP2C8) substrate repaglinide, P-glycoprotein (P-gp) transporter substrate digoxin, and breast cancer resistant protein (BCRP)/ organic anion transporter protein-1B1 (OATP1B1) transporter substrate rosuvastatin in healthy participants.

Conditions

Healthy Participants

Keywords

DC-806; Drug-drug interaction; Midazolam; Repaglinide; Digoxin; Rosuvastatin

Outcome Measures

Primary Outcomes (15)

• Cohort 1: Maximum Observed Plasma Concentration (Cmax) of Midazolam

  Day 1 and Day 7

• Cohort 1: Cmax of 1-hydroxymidazolam

  Day 1 and Day 7

• Cohort 1: Cmax of Repaglinide

  Day 1 and Day 7

• Cohort 2: Cmax of Digoxin

  Day 1 and Day 8

• Cohort 2: Cmax of Rosuvastatin

  Day 1 and Day 8

• Cohort 1: Area Under the Plasma Concentration-time Curve (AUC) up to Time t, Where t is the Last Point with Concentrations Above the Lower Limit of Quantification (AUC0-t) of Midazolam

  Days 1-3 and Days 7-9

• Cohort 1: AUC0-t of 1-hydroxymidazolam

  Days 1-3 and Days 7-9

• Cohort 1: AUC0-t of Repaglinide

  Days 1-3 and Days 7-9

• Cohort 2: AUC0-t of Digoxin

  Days 1-5 and Days 8-12

• Cohort 2: AUC0-t of Rosuvastatin

  Days 1-5 and Days 8-12

• Cohort 1: AUC from Time 0 to Infinity (AUC0-inf) of Midazolam

  Days 1-3 and Days 7-9

• Cohort 1: AUC0-inf of 1-hydroxymidazolam

  Days 1-3 and Days 7-9

• Cohort 1: AUC0-inf of Repaglinide

  Days 1-3 and Days 7-9

• Cohort 2: AUC0-inf of Digoxin

  Days 1-5 and Days 8-12

• Cohort 2: AUC0-inf of Rosuvastatin

  Days 1-5 and Days 8-12

Secondary Outcomes (1)

• Cohorts 1 and 2: Number of Participant who Experience an Adverse Event

  Up to a maximum 22 days

Study Arms (2)

Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)

EXPERIMENTAL

Participants will receive a single oral dose of the 2-probe substrate cocktail (midazolam and repaglinide) on Day 1. From Day 4 through Day 8, participants will receive twice-daily (BID) oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 7. DC-806 BID dosing will continue until the end of Day 8.

Drug: DC-806; Drug: Midazolam; Drug: Repaglinide

Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)

EXPERIMENTAL

Participants will receive a single oral dose of the 2-probe substrate cocktail (digoxin and rosuvastatin) on Day 1. From Day 5 through Day 9, participants will receive twice daily oral doses of DC-806 and a single oral dose of the 2-probe substrate cocktail on Day 8. DC-806 BID dosing will continue until the end of Day 9.

Drug: DC-806; Drug: Digoxin; Drug: Rosuvastatin

Interventions

DC-806 DRUG

Oral tablets

Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate); Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)

Midazolam DRUG

Oral syrup

Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)

Repaglinide DRUG

Oral tablets

Cohort 1: DC-806 + Midazolam (CYP3A4 substrate) + Repaglinide (CYP2C8 substrate)

Digoxin DRUG

Oral tablets

Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)

Rosuvastatin DRUG

Oral tablets

Cohort 2: DC-806 + Digoxin (P-gp substrate) + Rosuvastatin (BCRP/OATP1B1 substrate)

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Sex: male or female; females must be of nonchildbearing potential, or postmenopausal.
• Age: 18 to 55 years, inclusive, at screening.
• Body mass index: 18.0 to 32.0 kg/m\^2, inclusive, at screening.
• Weight: ≥50 kg at screening.
• Status: healthy participants.
• At screening, females must be of nonchildbearing potential (defined as at least 12 consecutive months with no menses prior to screening, a serum follicle-stimulating hormone test to confirm postmenopausal status, or being surgically sterilized); nonpregnancy will be confirmed for all females by a serum pregnancy test conducted at screening, and by a urine pregnancy test at admission and at follow-up.
• Male participants, if not permanently surgically sterilized, must inform all sexual partners of their participation in a research study and agree to use a highly effective method of contraception and not donate sperm from admission to the clinical site until 30 days after the last study drug administration.
• All prescribed medication must have been stopped at least 14 days prior to admission to the clinical site.
• All over-the-counter medication, vitamin preparations and other food supplements, or herbal medications (e.g., St. John's wort) must have been stopped at least 7 days (or 5 half-lives for certain medications, whichever is longer) prior to admission to the clinical site. Occasional use of acetaminophen/paracetamol (e.g., up to 2 grams per day) is permitted during this period and throughout the study.
• Ability and willingness to abstain from alcohol-, caffeine-, and methylxanthine- containing beverages or food (e.g., coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical site and during confinement at the clinical site.
• Willingness to abstain from any strenuous physical exercise from 96 hours (4 days) prior to admission and during confinement at the clinical site.
• Good physical and mental health on the basis of medical history, physical examination, clinical laboratory assessments, 12-lead electrocardiograms, and vital signs, as judged by the Investigator.
• Willing and able to sign the informed consent form.

You may not qualify if:

• Employee of Contract Research Organization or the Sponsor.
• History of relevant drug and/or food allergies, in the opinion of the Investigator.
• Females who are currently breastfeeding.
• Smoking more than 5 cigarettes, 1 cigar, or 1 pipe daily within 3 months prior to screening.
• Unwilling or unable to abstain from tobacco products within the 48 hours (2 days) prior to admission and during confinement in the clinical site.
• History of alcohol abuse or drug addiction (including soft drugs like cannabis products) within 1 year prior to screening.
• Positive drug and/or alcohol screen (opiates, methadone, cocaine, amphetamines \[including ecstasy\], cannabinoids, barbiturates, benzodiazepines, tricyclic antidepressants, and alcohol) at screening or admission to the clinical site.
• History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average. Alcohol consumption will be prohibited 48 hours prior to admission to the clinical site and during confinement at the clinical site.
• Positive screen for hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus 1 and 2 antibodies.
• Consumption of any nutrients known to modulate CYP450 enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, or Seville \[blood\] orange products) within 14 days prior to the first administration of study drug and during the study (including washout period/clinic furlough until after discharge in the last study period).
• Participation in a drug study within 30 days prior to study drug administration in the current study. Participation in 4 or more other drug studies in the 12 months prior to study drug administration in the current study.
• History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical site or planned donation before 30 days has elapsed since intake of study drug.
• Plasma or platelet donation within 7 days of dosing and through follow-up.
• Significant and/or acute illness within 5 days prior to study drug administration that may impact safety assessments, in the opinion of the Investigator.
• Unsuitable veins for infusion or blood sampling as determined by the Investigator or study staff.

Sponsors & Collaborators

• DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company: lead

Study Sites (1)

ICON Phase 1 Clinic

Salt Lake City, Utah, 84124, United States

Location

MeSH Terms

Interventions

Midazolam; repaglinide; Digoxin; Rosuvastatin Calcium

Intervention Hierarchy (Ancestors)

Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Digitalis Glycosides; Cardenolides; Cardiac Glycosides; Cardanolides; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Glycosides; Carbohydrates; Sulfonamides; Amides; Organic Chemicals; Fluorobenzenes; Hydrocarbons, Fluorinated; Hydrocarbons, Halogenated; Hydrocarbons; Sulfones; Sulfur Compounds; Pyrimidines; Heterocyclic Compounds, 1-Ring

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2023
• First Posted: October 23, 2023
• Study Start: October 16, 2023
• Primary Completion: November 28, 2023
• Study Completion: November 28, 2023
• Last Updated: January 11, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)